SELLAS Life Sciences Group, Inc. Marketable Securities, Unrealized Gain (Loss)
SELLAS Life Sciences Group, Inc. (SLS) reported Marketable Securities, Unrealized Gain (Loss) of $0 for the 12-month period ending 2015-12-31, per its 10-K/A filed 2016-04-15.
Discontinued › Income Statement › Other Income
us-gaap:MarketableSecuritiesUnrealizedGainLoss · last filed 2016-04-15
- SELLAS Life Sciences Group, Inc. marketable securities, unrealized gain (loss) for the quarter ending 2014-12-31 was $0.00, a 100.00% decline year-over-year.
- SELLAS Life Sciences Group, Inc. marketable securities, unrealized gain (loss) for the quarter ending 2014-09-30 was $0.00, a 100.00% decline year-over-year.
- SELLAS Life Sciences Group, Inc. marketable securities, unrealized gain (loss) for the quarter ending 2014-06-30 was $0.00, a 100.00% decline year-over-year.
- SELLAS Life Sciences Group, Inc. marketable securities, unrealized gain (loss) for the quarter ending 2014-03-31 was $0.00.
- SELLAS Life Sciences Group, Inc. marketable securities, unrealized gain (loss) for fiscal 2015 was $0.00.
- SELLAS Life Sciences Group, Inc. marketable securities, unrealized gain (loss) for fiscal 2013 was $2.68M.
| Period end | Marketable Securities, Unrealized Gain (Loss) 3 month | Marketable Securities, Unrealized Gain (Loss) 3 month as first filed | Marketable Securities, Unrealized Gain (Loss) 6 month | Marketable Securities, Unrealized Gain (Loss) 9 month | Marketable Securities, Unrealized Gain (Loss) 12 month | Marketable Securities, Unrealized Gain (Loss) 12 month as first filed | Marketable Securities, Unrealized Gain (Loss) 120 month | Marketable Securities, Unrealized Gain (Loss) 123 month | Marketable Securities, Unrealized Gain (Loss) 126 month |
|---|---|---|---|---|---|---|---|---|---|
| 2015-12-31 | $0.00 10-K/A · filed 2016-04-15 | ||||||||
| 2014-12-31 | $0.00 derived: 8-K 12 month − 10-Q 9 month · filed 2015-12-04 | $0.00 derived: sum of 2 quarters · filed 2015-12-04 | $0.00 derived: sum of 3 quarters · filed 2015-12-04 | $0.00 8-K · filed 2015-12-04 | |||||
| 2014-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2014-11-05 | $0.00 derived: sum of 2 quarters · filed 2014-11-05 | $0.00 10-Q · filed 2014-11-05 | $4.23M derived: sum of 4 quarters · filed 2016-04-15 | |||||
| 2014-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2014-08-11 | $0.00 10-Q · filed 2014-08-11 | $4.23M derived: sum of 3 quarters · filed 2016-04-15 | $5.79M derived: sum of 4 quarters · filed 2016-04-15 | |||||
| 2014-03-31 | $0.00 10-Q · filed 2014-05-06 | $4.23M derived: sum of 2 quarters · filed 2016-04-15 | $5.79M derived: sum of 3 quarters · filed 2016-04-15 | $9.71M derived: sum of 4 quarters · filed 2016-04-15 | |||||
| 2013-12-31 | $4.23M derived: 10-K/A 12 month − 10-Q 9 month · filed 2016-04-15 | $5.79M derived: sum of 2 quarters · filed 2016-04-15 | $9.71M derived: sum of 3 quarters · filed 2016-04-15 | $2.68M 10-K/A · filed 2016-04-15 | |||||
| 2013-09-30 | $1.56M derived: 10-Q 9 month − 10-Q 6 month · filed 2014-11-05 | $5.48M derived: sum of 2 quarters · filed 2014-11-05 | -$1.55M 10-Q · filed 2014-11-05 | -$1.55M derived: sum of 4 quarters · filed 2015-12-04 | |||||
| 2013-06-30 | $3.92M derived: 10-Q 6 month − 10-Q 3 month · filed 2014-08-11 | -$3.11M 10-Q · filed 2014-08-11 | -$3.11M derived: sum of 3 quarters · filed 2015-12-04 | -$5.79M 10-Q · filed 2013-08-09 | |||||
| 2013-03-31 | -$7.03M 10-Q · filed 2014-05-06 | $7.03M 10-Q · filed 2013-05-09 | -$7.03M derived: sum of 2 quarters · filed 2015-12-04 | $9.71M 10-Q · filed 2013-05-09 | |||||
| 2012-12-31 | $0.00 derived: 8-K 12 month − 10-K 9 month · filed 2015-12-04 | -$2.68M 8-K · filed 2015-12-04 | $2.68M 10-K · filed 2013-03-12 | $2.68M 10-K · filed 2013-03-12 | |||||
| 2012-09-30 | -$2.68M 10-K · filed 2014-03-17 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| uniQure N.V. (QURE) | $2.416B | -4.93 | |
| Vera Therapeutics, Inc. (VERA) | United States | $2.402B | -7.67 |
| Harmony Biosciences Holdings, Inc. (HRMY) | United States | $2.399B | 11.67 |
| Nurix Therapeutics, Inc. (NRIX) | United States | $2.457B | -5.39 |
| Mineralys Therapeutics, Inc. (MLYS) | United States | $2.353B | -6.82 |
| Viridian Therapeutics, Inc.\DE (VRDN) | United States | $2.342B | -5.38 |
| SUPERNUS PHARMACEUTICALS, INC. (SUPN) | United States | $2.517B | -24.63 |
| Immunome Inc. (IMNM) | United States | $2.538B | -9.45 |
| Disc Medicine, Inc. (IRON) | United States | $2.553B | -11.40 |
| Zai Lab Ltd (ZLAB) | $2.241B | -113.34 |